Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Soleno Therapeutics, Inc. - Common Stock (NQ:SLNO)

49.02 +0.91 (+1.88%)
Streaming Delayed Price Updated: 10:18 AM EST, Dec 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 101,763
Open 48.78
Bid (Size) 48.91 (500)
Ask (Size) 49.15 (300)
Prev. Close 48.12
Today's Range 48.04 - 49.41
52wk Range 41.50 - 90.32
Shares Outstanding 8,168,788
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Bragar Eagel & Squire, P.C. Encourages Agilon, Soleno, Avita, and Coty Investors to Contact the Firm Regarding Ongoing Investigations
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Soleno Therapeutics Unveils $100 Million Buyback Citing 'Underappreciated' Future ↗
Soleno Therapeutics (SLNO) approved $100M share repurchase program & entered ASR agreement with Jefferies LLC to buy back its stock. 
Via Benzinga

Performance

YTD
+7.3%
+7.3%
1 Month
-25.3%
-25.3%
3 Month
-27.1%
-27.1%
6 Month
-36.7%
-36.7%
1 Year
-2.0%
-2.0%

More News

Read More
News headline image
PubMatic Posts Upbeat Q3 Results, Joins Energy Vault, RealReal And Other Big Stocks Moving Higher On Tuesday ↗
Via Benzinga
News headline image
Earnings Scheduled For November 4, 2025 ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
SLNO INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Launches Investigation into Soleno Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law Firm
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Agilon, Soleno, Avita, and Coty and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
These stocks are moving in today's session ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Via Benzinga
News headline image
Wednesday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
Super Micro Computer Posts Downbeat Q1 Results, Joins Pinterest, Axon Enterprise And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
Via Benzinga
News headline image
These stocks that are showing activity before the opening bell on Wednesday. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Via Benzinga
News headline image
Why Teradata Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
What's going on in today's after hours session ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Via Benzinga
News headline image
Rosen Law Firm Encourages Soleno Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SLNO
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
SOLENO (SLNO) REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors of the Investigation into Soleno Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
Via Benzinga
News headline image
SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire

Frequently Asked Questions

Is Soleno Therapeutics, Inc. - Common Stock publicly traded?
Yes, Soleno Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Soleno Therapeutics, Inc. - Common Stock trade on?
Soleno Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Soleno Therapeutics, Inc. - Common Stock?
The ticker symbol for Soleno Therapeutics, Inc. - Common Stock is SLNO on the Nasdaq Stock Market
What is the current price of Soleno Therapeutics, Inc. - Common Stock?
The current price of Soleno Therapeutics, Inc. - Common Stock is 49.02
When was Soleno Therapeutics, Inc. - Common Stock last traded?
The last trade of Soleno Therapeutics, Inc. - Common Stock was at 12/03/25 10:18 AM ET
What is the market capitalization of Soleno Therapeutics, Inc. - Common Stock?
The market capitalization of Soleno Therapeutics, Inc. - Common Stock is 400.47M
How many shares of Soleno Therapeutics, Inc. - Common Stock are outstanding?
Soleno Therapeutics, Inc. - Common Stock has 400M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.